Australia and New Zealand In Vitro Diagnostics Market Report and Forecast 2024-2032
Australia and New Zealand In Vitro Diagnostics Market Report and Forecast 2024-2032
Australia and New Zealand In Vitro Diagnostics Market Outlook
The Australia and New Zealand in vitro diagnostics market size is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032, driven by innovation in molecular diagnostics and increasing expenditures and investments in the healthcare domain across the region.
In Vitro Diagnostics: Introduction
The in vitro diagnostics (IVD) market is a dynamic segment of the healthcare industry, primarily focused on the manufacture and use of medical devices and technologies for testing samples like blood, tissue, and urine outside the human body. Driven by technological advancements, increasing prevalence of chronic diseases, and a growing emphasis on early disease detection and personalized medicine, the market is witnessing substantial growth, with key players continuously innovating to meet the evolving healthcare demands.
Key Trends in the Australia and New Zealand In Vitro Diagnostics Market
Continuous innovation in molecular diagnostics, point-of-care testing, and next-generation sequencing technologies are enhancing accuracy and reducing turnaround times. Growing emphasis on personalized treatment approaches is driving demand for specific and targeted diagnostic tests.
The increasing incidence of chronic diseases such as diabetes, cancer, and cardiovascular disorders is prompting a higher demand for regular monitoring and early diagnosis. There's heightened regulatory oversight to ensure the reliability and accuracy of diagnostic tests, especially in the wake of the global health crises.
Integration of AI and machine learning in diagnostic procedures is improving predictive analytics, data management, and result interpretation. The market is witnessing a rise in demand for home-based testing kits and devices for conditions like diabetes and fertility, driven by consumer preference for convenience and privacy.
Laboratories are increasingly adopting automation to enhance productivity, reduce errors, and manage high test volumes. Increased health consciousness and awareness about preventive healthcare are leading to a rise in regular health check-ups and screenings.
Australia and New Zealand In Vitro Diagnostics Market Segmentation
Market Breakup by Technology
- Clinical Chemistry
- Molecular Diagnostics
- Immuno Diagnostics
- Hematology
- Others
- Instruments
- Reagents and Kits
- Services
- Data Management Software
- Infectious Disease
- Diabetes
- Cancer/Oncology
- Cardiology
- Autoimmune Disease
- Other Applications
- Diagnostic Laboratories
- Hospitals and Clinics
- Academic Institutes
- Point-of-Care Testing centers
- Others
- Australia
- New Zealand
In Australia, the in vitro diagnostics (IVD) market is marked by a strong emphasis on advanced technology integration and high-quality healthcare services. There's a growing trend towards personalized treatment, driving demand for genetic and molecular diagnostics to tailor therapies to individual patient profiles. The Therapeutic Goods Administration (TGA) ensures rigorous standards, influencing the introduction and quality of IVDs. Integration of digital solutions like AI and machine learning in diagnostic procedures is enhancing accuracy and efficiency. Also, there is a higher elderly population increases the prevalence of age-related diseases, boosting the demand for diagnostic services.
New Zealand’s IVD market trends are characterized by an inclusive healthcare approach and a focus on sustainable practices. Government programs emphasizing early disease detection and routine screening are propelling the IVD market. There's a significant interest in adopting cutting-edge diagnostic technologies, including point-of-care testing devices, offering rapid results. Efforts to improve diagnostic services in remote areas, ensuring wider access to healthcare facilities. There is a growing emphasis on eco-friendly medical products and waste management practices in healthcare facilities, aligning with the country's environmental conservation goals. Australia and New Zealand
Australia and New Zealand In Vitro Diagnostics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- BioMerieux SA
- F. Hoffmann-La Roche Ltd
- Becton, Dickinson and Company
- Bio-Rad Laboratories Inc.
- Abbott Laboratories, Inc.
- Siemens AG
- Thermo Fisher Scientific, Inc.
- QIAGEN N.V.
- Roche Diagnostics
- Danaher Corporation
- Agilent Technologies, Inc
- Quidel Corporation
- Diasorin S.P.A
- Illumina, Inc.
- Hologic, Inc
*Please Note:* The report will take 7 business days to complete, after order confirmation.
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Australia and New Zealand In Vitro Diagnostics Market Overview
- 3.1 Australia and New Zealand In Vitro Diagnostics Market Historical Value (2017-2023)
- 3.2 Australia and New Zealand In Vitro Diagnostics Market Forecast Value (2024-2032)
- 4 Australia and New Zealand In Vitro Diagnostics Market Dynamics
- 4.1 Market Drivers and Constraints
- 4.2 SWOT Analysis
- 4.3 Porter’s Five Forces Model
- 4.4 Key Demand Indicators
- 4.5 Key Price Indicators
- 4.6 Industry Events, Initiatives, and Trends
- 4.7 Value Chain Analysis
- 5 Australia and New Zealand In Vitro Diagnostics Market Segmentation
- 5.1 Australia and New Zealand In Vitro Diagnostics Market by Technology
- 5.1.1 Market Overview
- 5.1.2 Clinical Chemistry
- 5.1.3 Molecular Diagnostics
- 5.1.4 Immuno Diagnostics
- 5.1.5 Hematology
- 5.1.6 Others
- 5.2 Australia and New Zealand In Vitro Diagnostics Market by Product and Services
- 5.2.1 Market Overview
- 5.2.2 Instruments
- 5.2.3 Reagents and Kits
- 5.2.4 Services
- 5.2.5 Data Management Software
- 5.3 Australia and New Zealand In Vitro Diagnostics Market by Applications
- 5.3.1 Market Overview
- 5.3.2 Infectious Disease
- 5.3.3 Diabetes
- 5.3.4 Cancer/Oncology
- 5.3.5 Cardiology
- 5.3.6 Autoimmune Disease
- 5.3.7 Other Applications
- 5.4 Australia and New Zealand In Vitro Diagnostics Market by End User
- 5.4.1 Market Overview
- 5.4.2 Diagnostic Laboratories
- 5.4.3 Hospitals and Clinics
- 5.4.4 Academic Institutes
- 5.4.5 Point-of-Care Testing centers
- 5.4.6 Others
- 5.5 Australia and New Zealand In Vitro Diagnostics Market by Country
- 5.5.1 Market Overview
- 5.5.2 Australia
- 5.5.3 New Zealand
- 6 Patent Analysis
- 6.1 Analysis by Type of Patent
- 6.2 Analysis by Publication year
- 6.3 Analysis by Issuing Authority
- 6.4 Analysis by Patent Age
- 6.5 Analysis by CPC Analysis
- 6.6 Analysis by Patent Valuation
- 6.7 Analysis by Key Players
- 7 Grants Analysis
- 7.1 Analysis by year
- 7.2 Analysis by Amount Awarded
- 7.3 Analysis by Issuing Authority
- 7.4 Analysis by Grant Application
- 7.5 Analysis by Funding Institute
- 7.6 Analysis by NIH Departments
- 7.7 Analysis by Recipient Organization
- 8 Funding Analysis
- 8.1 Analysis by Funding Instances
- 8.2 Analysis by Type of Funding
- 8.3 Analysis by Funding Amount
- 8.4 Analysis by Leading Players
- 8.5 Analysis by Leading Investors
- 8.6 Analysis by Geography
- 9 Partnership and Collaborations Analysis
- 9.1 Analysis by Partnership Instances
- 9.2 Analysis by Type of Partnership
- 9.3 Analysis by Leading Players
- 9.4 Analysis by Geography
- 10 Regulatory Framework
- 10.1 Regulatory Overview
- 11 Supplier Landscape
- 11.1 BioMerieux SA
- 11.1.1 Financial Analysis
- 11.1.2 Product Portfolio
- 11.1.3 Demographic Reach and Achievements
- 11.1.4 Mergers and Acquisitions
- 11.1.5 Certifications
- 11.2 F. Hoffmann-La Roche Ltd
- 11.2.1 Financial Analysis
- 11.2.2 Product Portfolio
- 11.2.3 Demographic Reach and Achievements
- 11.2.4 Mergers and Acquisitions
- 11.2.5 Certifications
- 11.3 Becton, Dickinson and Company
- 11.3.1 Financial Analysis
- 11.3.2 Product Portfolio
- 11.3.3 Demographic Reach and Achievements
- 11.3.4 Mergers and Acquisitions
- 11.3.5 Certifications
- 11.4 Bio-Rad Laboratories Inc.
- 11.4.1 Financial Analysis
- 11.4.2 Financial Portfolio
- 11.4.3 Demographic Reach and Achievements
- 11.4.4 Mergers and Acquisitions
- 11.4.5 Certifications
- 11.5 Abbott Laboratories, Inc.
- 11.5.1 Financial Analysis
- 11.5.2 Product Portfolio
- 11.5.3 Demographic Reach and Achievements
- 11.5.4 Mergers and Acquisitions
- 11.5.5 Certifications
- 11.6 Siemens AG
- 11.6.1 Financial Analysis
- 11.6.2 Product Portfolio
- 11.6.3 Demographic Reach and Achievements
- 11.6.4 Mergers and Acquisitions
- 11.6.5 Certifications
- 11.7 Thermo Fisher Scientific, Inc.
- 11.7.1 Financial Analysis
- 11.7.2 Product Portfolio
- 11.7.3 Demographic Reach and Achievements
- 11.7.4 Mergers and Acquisitions
- 11.7.5 Certifications
- 11.8 QIAGEN N.V.
- 11.8.1 Financial Analysis
- 11.8.2 Product Portfolio
- 11.8.3 Demographic Reach and Achievements
- 11.8.4 Mergers and Acquisitions
- 11.8.5 Certifications
- 11.9 Roche Diagnostics
- 11.9.1 Financial Analysis
- 11.9.2 Product Portfolio
- 11.9.3 Demographic Reach and Achievements
- 11.9.4 Mergers and Acquisitions
- 11.9.5 Certifications
- 11.10 Danaher Corporation
- 11.10.1 Financial Analysis
- 11.10.2 Product Portfolio
- 11.10.3 Demographic Reach and Achievements
- 11.10.4 Mergers and Acquisitions
- 11.10.5 Certifications
- 11.11 Agilent Technologies, Inc
- 11.11.1 Financial Analysis
- 11.11.2 Product Portfolio
- 11.11.3 Demographic Reach and Achievements
- 11.11.4 Mergers and Acquisitions
- 11.11.5 Certifications
- 11.12 Quidel Corporation
- 11.12.1 Financial Analysis
- 11.12.2 Product Portfolio
- 11.12.3 Demographic Reach and Achievements
- 11.12.4 Mergers and Acquisitions
- 11.12.5 Certifications
- 11.13 Diasorin S.P.A
- 11.13.1 Financial Analysis
- 11.13.2 Product Portfolio
- 11.13.3 Demographic Reach and Achievements
- 11.13.4 Mergers and Acquisitions
- 11.13.5 Certifications
- 11.14 Illumina, Inc.
- 11.14.1 Financial Analysis
- 11.14.2 Product Portfolio
- 11.14.3 Demographic Reach and Achievements
- 11.14.4 Mergers and Acquisitions
- 11.14.5 Certifications
- 11.15 Hologic, Inc
- 11.15.1 Financial Analysis
- 11.15.2 Product Portfolio
- 11.15.3 Demographic Reach and Achievements
- 11.15.4 Mergers and Acquisitions
- 11.15.5 Certifications
- 12 Australia and New Zealand In Vitro Diagnostics Market - Distribution Model (Additional Insight)
- 12.1 Overview
- 12.2 Potential Distributors
- 12.3 Key Parameters for Distribution Partner Assessment
- 13 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 14 Company Competitiveness Analysis (Additional Insight)
- 14.1 Very Small Companies
- 14.2 Small Companies
- 14.3 Mid-Sized Companies
- 14.4 Large Companies
- 14.5 Very Large Companies
- 15 Payment Methods (Additional Insight)
- 15.1 Government Funded
- 15.2 Private Insurance
- 15.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook